Home
    Disclaimer
    PPAP molecular structure

    PPAP Stats & Data

    Dppea Mk-306 N,α-dipropylphenethylamine
    NPS DataHub
    MW241.8
    FormulaC14H24ClN
    IUPAC1-Phenyl-N-propylpentan-2-amine;hydrochloride
    SMILES[Cl-].CCCNC(CCC)Cc1ccccc1.[H+]
    InChIKeyQCJSIHKLYXENIM-UHFFFAOYSA-N
    Phenethylamines; 2020/1. Von 2-Phenethylamin abgeleitete Verbindungen; 2021/1. Von 2-Phenethylamin abgeleitete Verbindungen; 2022/1. Von 2-Phenethylamin abgeleitete Verbindungen
    Chemical Class Amphetamine
    Psychoactive Class Stimulant
    Half-Life Unknown in humans; subjective offset suggests several hours (roughly 4–6 h) but confidence is low.

    Effect Profile

    Curated
    Stimulant 5.6

    Moderate euphoria, focus, and anxiety/jitters with mild stimulation

    Stimulation / Energy×3
    5
    Euphoria / Mood Lift×2
    7
    Focus / Productivity×2
    6
    Anxiety / Jitters×1
    6

    Tolerance & Pharmacokinetics

    drugs.wiki
    Half-Life
    Unknown in humans; subjective offset suggests several hours (roughly 4–6 h) but confidence is low.
    Addiction Potential
    Low-to-moderate. Classic euphoria and reinforcement appear modest compared with dopaminergic releasers, but some users report anxiety/insomnia and increasing reliance with frequent use. Prefer intermittent dosing and planned breaks; avoid daily use.

    Tolerance Decay

    Full tolerance 3d Half tolerance 4d Baseline ~10d

    Patterns are based on user reports: repeated daily dosing for multiple days appears to reduce desired effects and increase anxiety/insomnia; spacing use by several days to a week helps preserve efficacy. Cross-tolerance with other CAE/MAE agents (e.g., BPAP) is plausible but unquantified. Data quality is limited.

    Cross-Tolerances

    selegiline
    30% ●○○
    BPAP
    50% ●○○

    Harm Reduction

    drugs.wiki

    Mechanism: PPAP is a deprenyl-derived catecholaminergic activity enhancer that increases impulse-dependent transmitter release without acting as a classical releaser or reuptake inhibitor; it also lacks measurable MAO inhibitory potency in preclinical work. This helps explain smoother stimulation with less stereotypy than amphetamine. Animal studies suggest PPAP and deprenyl enhance action potential–transmitter release coupling and increase inward Ca2+ current in sinoatrial fibers, implying dose-related effects on heart rate; persons with cardiovascular disease, arrhythmias, or uncontrolled hypertension should avoid use or seek medical advice first. Human data are sparse; virtually all dosing and ROA information is anecdotal. Users often report clear-headed stimulation, increased task engagement, and minimal crash at 20–60 mg oral; anxiety and insomnia become more likely at higher or late-day doses. Combining PPAP with other stimulants is not reliably synergistic: preclinical data describe bidirectional antagonism with amphetamine/mazindol on locomotion, and community reports sometimes note blunted effects of other stimulants when co-administered; due to unpredictability and cardiovascular load, avoid such combinations. For sublingual use, some report local irritation/burning; test with very low amounts first. Parenteral routes (IM/IV) markedly increase infection and tissue-risk; oral or sublingual routes are safer. Use an accurate milligram scale; volumetric dosing (dissolving a known amount of the HCl salt into a measured volume) can improve precision when scales are unreliable. Appearance does not predict identity or purity; where available, use accredited drug checking (FTIR/GC-MS) services, as simple color reagents will not confirm PPAP identity. Space doses to manage tolerance and sleep: many users take at least several days off between uses and avoid dosing after mid-afternoon to reduce insomnia. Store in airtight, light-protected containers in a cool, dry place to limit degradation; avoid humidity.

    ← Back to PPAP